Video

Dr. Salles on Improving Immune Respone in Follicular Lymphoma

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Agents such as lenalidomide (Revlimid) are being explored in the treatment landscape of follicular lymphoma to trigger immune responses in patients with follicular lymphoma. Anti—PD-1/PD-L1 agents may potentially be used to develop these responses as well, says Salles.

This is a step toward a rational understanding of how the immune system fights and can tackle lymphoma and, according to Salles, it may spare patients chemotherapy if effective.

Related Videos
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University